Posts

New antibody suppresses HIV for 28 days after single dose

A new lab-made antibody can suppress HIV for up to 28 days after only a single dose, researchers at the Rockefeller University in New York have found.

Their work was published in the journal Nature on 8 April and was the first time that a new generation of HIV antibodies had been tested in humans.

‘We conclude that, as a single agent, 3BNC117 is safe and effective in reducing HIV-1 viraemia, and that immunotherapy should be explored as a new modality for HIV-1 prevention, therapy and cure,’ wrote the study’s lead author, Michel Nussenzweig.

Full article

AIDS 2014 : OFFICIAL PRESS RELEASE – DAY 1

Tributes paid to lost colleagues aboard flight MH 17 at the Opening Session of the 20th International AIDS Conference in Melbourne, Australia

World leaders, researches, activists and policymakers applaud global progress in the HIV response and urged to address stigma and discrimination

Some 12,000 participants from all over the world have gathered in Melbourne for the start of the 20th International AIDS Conference (AIDS 2014). Under the theme Stepping up the Pace, during the five days of the conference delegates will discuss the latest research developments and will hear about the status of the epidemic from world renowned experts. The conference runs through until Friday, 25 July at the Melbourne Convention and Exhibition Centre.

AIDS 2014 will offer delegates a strong scientific programme with presentations around hot topics including HIV cure strategies and challenges; HIV prevention via Pre-Exposure Prophylaxis (PrEP), Treatment as Prevention (TasP), and voluntary medical male circumcision; Tuberculosis and Hepatitis C co-infection; and HIV and hormonal contraception. In addition, several studies will discuss the impact of discriminatory laws and the costs related to HIV prevention and care.

At the AIDS 2014 Opening Sessions, speakers discussed the encouraging data related to access treatment and reducing new HIV infections, but reminded the audience that HIV is far from being defeated and that stigma and discrimination towards Key Affected Population pose a major barrier to the end of the epidemic.

“The tremendous scale-up of HIV programmes has, for so many people transformed HIV from a death sentence into a chronically manageable disease,” Professor Françoise Barré-Sinoussi, AIDS 2014 International Chair, President of the International AIDS Society (IAS) and Director of the Regulation of Retroviral Infections Unit at the Institut Pasteur in Paris told delegates attending the opening session on Sunday night.

“One-third of people living with HIV, who need treatment now have access to it.

Click to Read Full Press Release